Pricing erosion in US biosimilars
Competitive pressure and ASP declines in medical benefit products could impact margins.
medium · analyst_question
Biocon Limited — Q4 FY26
Biocon delivered a strong Q4 FY26, with adjusted revenue growth of 10% YoY and EBITDA up 29% YoY to ₹1,073 crore, driven by favorable mix and operating leverage in biosimilars.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Chinese competition in insulin
Recent Chinese approvals in insulin could disrupt pricing and market share.
medium · analyst_questionCRDMO revenue growth slowdown
Syngene's FY26 revenue grew only 3% YoY due to a large client impact; recovery uncertain.
medium · data_observationExecution risk on new product launches
Ramp-up of aspart and aflibercept depends on capacity qualification and market adoption.
low · management_commentary